Company Overview
Spyre Therapeutics, Inc. operates as a clinical stage biotechnology company dedicated to developing therapeutics for patients suffering from inflammatory bowel disease and rheumatic diseases. The firm's primary focus involves the development of SPY001, a humanized monoclonal immunoglobulin G1 antibody currently progressing through phase-2 clinical trials. This company functions within the healthcare sector and specifically the biotechnology industry, where it seeks to advance treatments for chronic inflammatory conditions. The organization employs a workforce of 102 individuals to support its research and development objectives. With a market capitalization of $3.32B, Spyre Therapeutics represents a substantial entity within the biotech landscape, despite the absence of reported annual revenue figures in the provided data. The company's market cap indicates significant market valuation relative to its current financial reporting status, which is common for clinical-stage firms focused on high-value drug candidates. The disparity between the large market cap and the lack of revenue highlights the company's reliance on future clinical outcomes and regulatory approvals to drive future financial performance. This valuation reflects investor confidence in the potential of its pipeline, specifically the SPY001 candidate, to generate future economic value upon commercialization.
Financial Health
The company reports net income of $-126,542,000 for the trailing twelve months, while revenue and EBITDA figures are not available in the current dataset. The significant gap between reported revenue (which is N/A) and the substantial net loss reveals a cost structure dominated by research and development expenditures typical of early-stage biotechnology ventures. Free cash flow stands at $-103,849,248, indicating that the company is burning cash to fund its clinical trials and operational expansion rather than generating operational liquidity. This negative free cash flow position necessitates a reliance on external capital markets or existing cash reserves to sustain operations until product approval. All three margin metrics—gross margin, operating margin, and profit margin—are reported at 0.0%, which indicates that the company has not yet achieved profitability or that revenue data is insufficient to calculate standard margins due to the lack of commercial sales. The balance sheet shows a cash position of $756.53M against N/A total debt, with a debt-to-equity ratio listed as N/A, suggesting a balance sheet that is primarily funded by equity and cash rather than significant leverage. The current ratio is an exceptionally high 13.25, which indicates strong short-term liquidity and the ability to cover short-term obligations many times over with existing current assets. Return on Equity is -25.2% and Return on Assets is -19.8%, metrics that reveal management is currently utilizing shareholder capital and assets to generate losses rather than profits, a common characteristic for companies in the clinical development phase.
Valuation Assessment
The trailing twelve months P/E ratio is N/A due to the lack of net income, while the forward P/E is -14.10, implying that future earnings projections are negative or that the market is pricing in a path to profitability far in the future. The price-to-book ratio is 5.91, which indicates that the market is valuing the company at nearly six times its book value, suggesting a significant premium assigned to its intellectual property and clinical pipeline over its tangible net assets. The price-to-sales ratio is N/A and the EV/EBITDA is N/A, meaning these alternative valuation metrics cannot be calculated from the current financial data, reflecting the pre-revenue or pre-profitability nature of the enterprise. The 52-week high is $45.76 and the 52-week low is $10.91, establishing a wide trading range that underscores the high volatility typical of small-cap biotechnology stocks. The stock is currently positioned somewhere within this range, with the beta of 3.12 indicating that the share price is expected to be 3.12 times as volatile as the broader market. This high beta value signifies that price movements in Spyre Therapeutics will likely be amplified relative to general market shifts, making the asset highly sensitive to sector-specific news and clinical trial updates.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both N/A, precluding an analysis of historical growth rates due to the absence of comparable prior period revenue data. The company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which implies that the firm reinvests all available resources back into research, development, and clinical operations rather than distributing income to shareholders. Given the negative net income and lack of free cash flow, the 0.0% payout ratio is structurally consistent with a company that must retain all earnings to fund its operations. The overall growth and income profile is characterized by a complete absence of current income generation and historical growth metrics, relying entirely on the potential future success of its SPY001 therapeutic candidate. This profile places the stock in a category where returns are driven exclusively by capital appreciation based on clinical milestones rather than current financial performance or dividend income.